Regorafenib Composition for COPD Immune Response Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic obstructive pulmonary disease (COPD) are inadequate due to high side effects and insufficient therapeutic efficacy, particularly for long-term management, and there is a need for a more effective therapeutic agent to address the disease's progressive nature and increasing mortality rate.
Innovation Solution
A pharmaceutical composition containing regorafenib or its pharmaceutically acceptable salt is developed, which inhibits immune response by reducing the proliferation of immune cells and secretion of inflammatory mediators, thereby decreasing alveolar size and improving lung function in COPD patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If steroids and anti-inflammatory drugs are used to reduce inflammation in lung tissue, then inflammatory response is suppressed, but side effects increase and therapeutic efficacy becomes insufficient for long-term treatment
Solution Approach 1:
The patent applies parameter changes by switching from traditional steroid/anti-inflammatory drug mechanisms to a different pharmacological mechanism involving regorafenib, which modulates immune cell function through alternative pathways. This changes the therapeutic parameter from broad anti-inflammatory suppression to targeted immune response modulation, achieving inflammation control with improved safety and long-term efficacy profiles
2Object-affected harmful factors
If conventional COPD treatments are used, then some inflammatory symptoms are managed, but therapeutic effect is insufficient and mortality rate continues to increase
Solution Approach 1:
The patent introduces regorafenib as an intermediary substance that mediates the therapeutic effect in COPD treatment. This compound acts as a novel mediator that modulates immune cell activity and inflammatory pathways differently from conventional drugs, providing enhanced therapeutic effect and addressing the insufficiency of current treatments
Data Source
AI summary
Disclosed is a composition for preventing or treating chronic obstructive pulmonary disease containing regorafenib as an active ingredient, and particularly a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease containing regorafenib or a pharmaceutically acceptable salt thereof as an active ingredient, in which regorafenib is capable of effectively inhibiting increased immune response, which is a symptom of chronic obstructive pulmonary disease, and of improving and restoring changed lung structure and damaged lung function, and can be effectively used for the manufacture of a medicament for the prevention, amelioration, or treatment of chronic obstructive pulmonary disease, such as emphysema, chronic bronchitis, asthma, or pneumonia.